Harry Sloan Biography and Net Worth

Director of Ginkgo Bioworks

Harry E. Sloan is the Chairman and CEO of Eagle Equity Partners II, LLC. Under Sloan’s leadership, the company has acquired and taken public, through SPACs, several companies including, during 2020, DraftKings and mobile gaming company Skillz. Earlier in his career, Sloan was the Chairman and CEO of MGM Studios and founded and led two public companies in the entertainment media arena, New World Entertainment and SBS Broadcasting, S.A., one of Europe’s largest broadcasters. Sloan is an Associate Professor at the UCLA Anderson School of Management and is a Trustee of The McCain Institute. Sloan earned a B.A. from UCLA and a J.D. from Loyola Law School.

What is Harry Sloan's net worth?: The estimated net worth of Harry Sloan is at least $1.67 million as of June 14th, 2024. Mr. Sloan owns 250,000 shares of Ginkgo Bioworks stock worth more than $1,666,250 as of March 27th. This net worth evaluation does not reflect any other investments that Mr. Sloan may own. Learn More about Harry Sloan's net worth.
How do I contact Harry Sloan?: The corporate mailing address for Mr. Sloan and other Ginkgo Bioworks executives is 955 Fifth Avenue, New York NY, 10075. Ginkgo Bioworks can also be reached via phone at 877-442-5362 and via email at investors@ginkgobioworks.com. Learn More on Harry Sloan's contact information.
Has Harry Sloan been buying or selling shares of Ginkgo Bioworks?: Harry Sloan has not been actively trading shares of Ginkgo Bioworks during the last ninety days. Most recently, on Tuesday, May 14th, Harry Sloan bought 297,619 shares of Ginkgo Bioworks stock. The stock was acquired at an average cost of $0.91 per share, with a total value of $270,833.29. Following the completion of the transaction, the director now directly owns 718,540 shares of the company's stock, valued at $653,871.40. Learn More on Harry Sloan's trading history.
Who are Ginkgo Bioworks' active insiders?: Ginkgo Bioworks' insider roster includes Barry Canton (Major Shareholder), Marijn Dekkers (Director), Mark Dmytruk (Insider), Christian Henry (Director), Jason Kelly (Insider), Reshma Shetty (Insider), and Harry Sloan (Director). Learn More on Ginkgo Bioworks' active insiders.
Are insiders buying or selling shares of Ginkgo Bioworks?: In the last twelve months, Ginkgo Bioworks insiders bought shares 1 times. They purchased a total of 297,619 shares worth more than $270,833.29. In the last twelve months, insiders at the sold shares 11 times. They sold a total of 410,143 shares worth more than $348,274.49. The most recent insider tranaction occured on March, 4th when insider Steven P Coen sold 395 shares worth more than $3,049.40. Insiders at Ginkgo Bioworks own 9.7% of the company. Learn More about insider trades at Ginkgo Bioworks.
Information on this page was last updated on 3/4/2025.

Harry Sloan Insider Trading History at Ginkgo Bioworks

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/14/2024	Buy	297,619	$0.91	$270,833.29	718,540

Harry Sloan Buying and Selling Activity at Ginkgo Bioworks

Ginkgo Bioworks Company Overview

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $6.67

$6.59

$7.13

50 Day Range

MA: $10.58

$6.46

$16.38

2 Week Range

Now: $6.67

$5.26

$48.00

Volume

1,311,192 shs

Average Volume

1,419,755 shs

Market Capitalization

$386.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.23